Baidu
map

呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

Thorax：COPD患者抗衰老因子-生长分化因子11减少！

2017-04-29 xing.T MedSci原创

COPD抗衰老因子GDF11
关注

由此可见，GDF11的减少可能参与了COPD患者肺脏中的细胞衰老。

慢性阻塞性肺病（COPD）患者的肺脏中可以观察到细胞衰老，并可能参与了疾病的发病机制。生长分化因子11（GDF11）属于转化生长因子β超家族的成员，最近有研究报道小鼠中GDF11是一种具有重返年轻效应的循环蛋白质。近日，胸部疾病领域权威杂志Thorax上发表了一篇研究文章，研究人员旨在探讨COPD患者肺脏中血浆中GDF11的数量，并且阐明GDF11在细胞衰老中可能发挥的作用。

在两个独立的队列中，研究人员采用Western蛋白印迹方法检测了血浆中GDF11的浓度，分别采用免疫组织化学和定量反转录PCR的方法检测了肺脏中GDF11的定位和表达。研究人员在体外观察了GDF11对香烟烟雾提取物（CSE）诱导的细胞衰老的影响，以及体内观察了GDF11对弹性蛋白酶诱导的细胞衰老的影响。

研究人员发现在两个独立的队列中COPD患者血浆中GDF11的水平相比于对照者明显下降。血浆中GDF11水平与肺功能数据呈显著的正相关。在COPD患者间充质细胞中GDF11的mRNA水平表达降低。慢性暴露于CSE可以降低GDF11的表达。在体外实验中，采用GDF11处理可以显著抑制CSE诱导的细胞衰老和炎症介质的表达上调，部分是通过Smad2/3信号。每日采用GDF11治疗可以减缓弹性蛋白酶诱导的肺气肿动物模型细胞衰老和空隙扩大。

由此可见，GDF11的减少可能参与了COPD患者肺脏中的细胞衰老。

原始出处：

Katsuhiro Onodera, et al. Decrease in an anti-ageing factor, growth differentiation factor 11, in chronic obstructive pulmonary disease.Thorax. 2017. http://dx.doi.org/10.1136/thoraxjnl-2016-209352

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053967, encodeId=1e32205396efa, content=<a href='/topic/show?id=679755e8230' target=_blank style='color:#2F92EE;'>#抗衰老因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55782, encryptionId=679755e8230, topicName=抗衰老因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Sep 13 05:43:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198624, encodeId=e5051986247f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 16 06:15:25 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196845, encodeId=9f6419684596, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 12 06:14:06 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488796, encodeId=85871488e9681, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Mon May 01 06:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191969, encodeId=86a61919692a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Apr 30 00:15:08 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-09-13 智者为医08

    #抗衰老因子#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2053967, encodeId=1e32205396efa, content=<a href='/topic/show?id=679755e8230' target=_blank style='color:#2F92EE;'>#抗衰老因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55782, encryptionId=679755e8230, topicName=抗衰老因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Sep 13 05:43:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198624, encodeId=e5051986247f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 16 06:15:25 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196845, encodeId=9f6419684596, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 12 06:14:06 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488796, encodeId=85871488e9681, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Mon May 01 06:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191969, encodeId=86a61919692a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Apr 30 00:15:08 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-05-16 1e145228m78(暂无匿称)

    学习了，谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2053967, encodeId=1e32205396efa, content=<a href='/topic/show?id=679755e8230' target=_blank style='color:#2F92EE;'>#抗衰老因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55782, encryptionId=679755e8230, topicName=抗衰老因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Sep 13 05:43:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198624, encodeId=e5051986247f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 16 06:15:25 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196845, encodeId=9f6419684596, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 12 06:14:06 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488796, encodeId=85871488e9681, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Mon May 01 06:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191969, encodeId=86a61919692a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Apr 30 00:15:08 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-05-12 1e145228m78(暂无匿称)

    学习了，谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2053967, encodeId=1e32205396efa, content=<a href='/topic/show?id=679755e8230' target=_blank style='color:#2F92EE;'>#抗衰老因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55782, encryptionId=679755e8230, topicName=抗衰老因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Sep 13 05:43:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198624, encodeId=e5051986247f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 16 06:15:25 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196845, encodeId=9f6419684596, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 12 06:14:06 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488796, encodeId=85871488e9681, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Mon May 01 06:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191969, encodeId=86a61919692a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Apr 30 00:15:08 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-05-01 gous

    #COPD患者#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2053967, encodeId=1e32205396efa, content=<a href='/topic/show?id=679755e8230' target=_blank style='color:#2F92EE;'>#抗衰老因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55782, encryptionId=679755e8230, topicName=抗衰老因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Sep 13 05:43:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198624, encodeId=e5051986247f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 16 06:15:25 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196845, encodeId=9f6419684596, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 12 06:14:06 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488796, encodeId=85871488e9681, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Mon May 01 06:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191969, encodeId=86a61919692a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Apr 30 00:15:08 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-04-30 tanxingdoctor

    学习了谢谢分享

    0

相关资讯

Environ Pollut:PM2.5与COPD关系

经济发展给人们带来便利的同时，也产生了许多困扰。环境问题的日益突出引起了人们的重视，PM2.5成为当前的热点话题。近期在Environ Pollut杂志上的一篇文章就PM2.5与慢性阻塞性肺疾病（COPD）的关系进行了研究。COPD与T淋巴细胞亚群（Th1/Th2, Th17/Treg）的失衡有关。 Notch 信号通路在获得性免疫的发展中有着重要的作用。PM2.5所诱发的免疫

Environ Pollut：PM2.5危害调查研究

随着经济的发展，环境问题日益突出。PM2.5和我们的生活与健康息息相关。最近Environ Pollut中一篇文章对印度圣城瓦拉纳西进行了关于PM2.5对人体影响的调查。因为长期暴露于高水平的细颗粒物质（PM2.5）中，选取约有3百万居住人口的印度圣城瓦拉纳西及其郊区作为研究对象。直到2015年中央污染委员会才开始对这座城市进行连续的监测，所以，其过去的污染水平是如何的以及这些年的变化情况也都是未

Chest：吸氧对COPD患者6分钟步行试验结果的短期影响

与NOX相比， HYX和EIH患者能通过吸氧增加运动能力。然而达到临床改善阈值的患者还不到一半。这些氧气应答者的特点是运动能力水平显著下降。

Heart：伴有CVD高风险的COPD患者采用吸入性β2-受体激动剂和糖皮质激素治疗的心血管结局如何？

由此可见，在有中度气流受限和CVD风险增高的COPD患者中，给予吸入的VI、FF或其联合治疗具有良好的安全性，并且不会影响CVD结局。

Oncotarget：吸入性糖皮质激素能预防肺癌发生？

近期，Oncotarget杂志中一篇文章报道：使用吸入性糖皮质激素（ICS）治疗COPD的同时，也有助于预防肺癌的发生。该研究者在全国进行了一项以人群为基础的队列研究，从台湾全民健康保险数据库中提取了13686名COPD女性的患者(ICS使用者，N=1290；未使用ICS，N=12396)的资料，这些患者均是在1997-2009期间确诊为COPD。对这些患者进行随访直到2011年，对肺癌的发病率进

Chest：COPD-OSA重叠综合征

慢性阻塞性肺疾病（COPD）和阻塞性睡眠呼吸暂停综合征（OSA）是常见的两种疾病，这也意味着，基于机会联合，这两种疾病合并发生（重叠综合征）可能也是常见的。然而，COPD不同的临床表型影响着共存的OSA的可能性，因为与肺气肿表型相关一些因素，如增加的肺容积和低体重指数（BMI）对OSA的发生具有一定的预防作用，而与慢性支气管炎表型相关的外周水肿和BMI的增加又可以促进OSA的发生。COPD和OSA

Baidu
map
Baidu
map
Baidu
map